home / stock / adms / adms news

ADMS News and Press, Adamas Pharmaceuticals Inc.

Stock Information
Company Name: Adamas Pharmaceuticals Inc.
Stock Symbol: ADMS
Market: NASDAQ
Website: adamaspharma.com
Menu
ADMS ADMS Quote ADMS Short ADMS News ADMS Articles ADMS Message Board
Get ADMS Alerts

News, Short Squeeze, Breakout and More Instantly...
ADMS - Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline

NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members. For the purp...
ADMS - $4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000 to benefit class members. For the purp...

ADMS - Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members. For the pur...

ADMS - Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of $4,650,000 to benefit class members. For the pur...
ADMS - Supernus up 10% following 2021 earnings guidance boost, Q3 beat

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) are up ~10% in after-hours trading after the company boosted its full-year earnings guidance and beat Q3 earnings estimates. Operating earnings for 2021 are now expected to be $90M-$95M, up from prior guidance of $70M-$90M. Net produc...

ADMS - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, DSPG, HRC, CXP; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 1, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) concerning potential violations of the federal securities laws and/or breaches of fiducia...

ADMS - Adamas Pharmaceuticals: An Acceptable Buyout At The Perfect Time

Adamas Pharmaceuticals announced that Supernus Pharmaceuticals has struck a deal to buy ADMS at $8.10 per share with CVR kickers. I believe this is a perfect time for both companies. Supernus' leading product, Trokendi, is moving closer to its patent expiration in 2023. GOCOVRI might ...
ADMS - SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciar...

ADMS - Why Supernus' Acquisition of Adamas Is a Smart Move

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...

ADMS - Merger Arbitrage Mondays: Emerson Combines Industrial Software Businesses With Aspen Technology

Potential deal in the works Aspen Technology materializes. Two deals with Contingent Value Rights announced last week. Navios Maritime Partners completed the acquisition of Navios Maritime Acquisition Corporation. For further details see: Merger Arbitrage Mondays: Emerso...
Next 10